Currently we test and support the following browsers:
Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
St. Jude Children’s Research Hospital—Washington University Pediatric Cancer Genome Project finds TP53 gene is altered in nearly all osteosarcomas; results help explain how tumors withstand radiation therapy. (Michael Dyer, PhD, and Jinghui Zhang, PhD)
Even cancer cells can feel stress. In fact, it can kill them. According to new research led by St. Jude Children’s Research Hospital, drugs that enhance a process called oxidative stress may offer a new way to combat an aggressive soft tissue tumor called rhabdomyosarcoma.
St. Jude Children’s Research Hospital–Washington University Pediatric Cancer Genome Project study identifies drugs that enhance oxidative stress as possible weapon against most common pediatric soft tissue tumor. (Dr. Michael Dyer)
Michael Dyer, Ph.D., of St. Jude Children's Research Hospital, has been recognized as one of the nation’s leading biomedical researchers by the Howard Hughes Medical Institute.
Pediatric Cancer Genome Project scientists begin to uncover treasures.
St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project and Memorial Sloan-Kettering Cancer Center discover first gene alteration associated with patient age and neuroblastoma outcome. (Dr. Michael Dyer)
St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project findings help solve mystery of retinoblastoma’s rapid growth in work that also yields a new treatment target and possible therapy. (Dr. Michael Dyer)
St. Jude Children’s Research Hospital scientists lead research that settles a century-old debate about retinoblastoma’s beginnings and identify new targets for treating the childhood eye tumor
Investigators believe they have identified the founding member of a chemical family they hope will lead to a new class of cancer drugs, the first designed specifically against a childhood tumor, according to research led by St. Jude Children’s Research Hospital scientists.
The wait is over for scientists at St. Jude who envisioned the day when technology would transform the way they analyze DNA samples. Using new technology that churns out massive amounts of data, investigators now have a comprehensive view of genomes to increase their understanding of cancers and infectious diseases.
Researchers comparing the fetal development of the eye of the owl monkey with that of the capuchin monkey have found that only a minor difference in the timing of cell proliferation can explain the multiple anatomical differences in the two kinds of eyes.
Cells isolated from the eye that many scientists believed were retinal stem cells are, in fact, normal adult cells, investigators at St. Jude have found. If retinal stem cells could be obtained, they might provide the basis for treatments to restore sight to millions of people with blindness caused by retinal degeneration.
Michael Dyer, a faculty member at St. Jude Children's Research Hospital, has been tapped as one of the nation’s leading scientists by the Howard Hughes Medical Institute.
An electron microscope uses a beam of electrons to produce highly detailed images that reveal a specimen’s structure and composition. The new instrument, one of only 200 of its type in the world, is the centerpiece of a recent expansion of cellular imaging at St. Jude.
St. Jude investigators disprove a century-old theory, turning established scientific beliefs on their heads. This exciting discovery may someday have applications for such diseases as Alzheimer’s and Parkinson’s.
Researchers found that certain mutations enable specific cells in the retina to multiply and cause eye cancer, a finding that suggests deliberate genetic manipulations might coax an injured brain to repair itself.
A team of St. Jude investigators challenged conventional wisdom about the eye cancer retinoblastoma by using a mouse model that allowed them to study the tumors as they develop and grow.
St. Jude scientists have demonstrated in the laboratory a new treatment for retinoblastoma that reduces the size of the tumor without causing the side effects common with standard chemotherapy.
Investigators at St. Jude have discovered the role of several key genes in the development of the retina, and in the process have taken a significant step toward understanding how to prevent or cure the potentially deadly eye eye cancer retinoblastoma.
Investigators at St. Jude have demonstrated in laboratory studies a potential new treatment for the pediatric eye cancer retinoblastoma that appears to be more effective than the current standard therapy.
The development of a laboratory model for a rare, inherited form of blindness holds promise that scientists might one day be able to test new treatments to prevent or cure this devastating disease of the retina.
Michael Dyer, PhD, an assistant member of Developmental Neurobiology, has been named a 2004 Pew Scholar.
The development of a mouse model that closely mimics the human eye cancer retinoblastoma, gives investigators a way to test new therapies for this disease in the laboratory for the first time.
Children with retinoblastoma reap the benefits of basic laboratory research while St. Jude researchers harness technology and knowledge to give clinicians a vast array of treatment options.